Arnaud Zabala

Mr. Arnaud Zabala

University of Bordeaux, Bordeaux, Nouvelle-Aquitaine, France
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
FDFrederic C. Daoud
Frederic C. Daoud
FMFatima M’Zali
Fatima M’Zali
AZArnaud Zabala
Arnaud Zabala
NMNicholas Moore
Nicholas Moore
ARAnne-Marie Rogues
Anne-Marie Rogues
(1) Background: Three antimicrobial absorbable sutures have different triclosan (TS) loads, triclosan release kinetics and hydrolysis times. This in vitro study aims to analyse and compare their antimicrobial pharmacodynamics. (2) Methods: Time-kill assays were performed with eight triclosan-susceptible microorganisms common in surgical site infections (SSIs) and a segment of each TS. Microbial concentrations were measured at T0, T4, T8 and T24 h. Similar non-triclosan sutures (NTS) were used as controls. Microbial concentrations were plotted and analysed with panel analysis. They were predicted over time with a double-exponential model and four parameters fitted to each TS × microorganism combination. (3) Results: The microbial concentration was associated with the triclosan presence, timeslot and microorganism. It was not associated with the suture material. All combinations shared a common pattern with an early steep concentration reduction from baseline to 4–8 h, followed by a concentration up to a 24-h plateau in most cases with a mild concentration increase. (4) Conclusions: Microorganisms seem to be predominantly killed by contact or near-contact killing with the suture rather than the triclosan concentration in the culture medium. No significant in vitro antimicrobial pharmacodynamic difference between the three TS is identified. Triclosan can reduce the suture microbial colonisation and SSI risk.

13 January 2022 in Nephrologie & Therapeutique
Verified
Journal Article
Closed access
MAMathieu Acquier
Mathieu Acquier
VPValérie De Précigout
Valérie De Précigout
YDYahsou Delmas
Yahsou Delmas
VDVéronique Dubois
Véronique Dubois
FMFatima M’zAli
Fatima M’zAli
HKHannah Kaminski
Hannah Kaminski
La population de patients traités par hémodialyse sur cathéter est fragile, à risque infectieux important. La bactériémie liée au cathéter d’hémodialyse est l’une des complications les plus graves, dont l’incidence augmente chaque année, en lien avec une hausse de l’utilisation des cathéters comme abord vasculaire. Cependant, le diagnostic clinique et microbiologique reste difficile. La mise en place de l’antibiothérapie probabiliste se base sur des recommandations anciennes qui préconisent d’associer une molécule visant le Staphylococcus aureus méticillino-résistant, ainsi qu’une bêtalactamine active sur P. aeruginosa, mais également d’adapter ce traitement probabiliste en réalisant un recueil microbiologique à l’échelle locale, ce qui est rarement réalisé. Dans notre centre d’hémodialyse du CHU de Bordeaux, une analyse de la répartition bactériologique des bactériémies liées au cathéter d’hémodialyse sur la période 2018–2020 a permis de proposer, en accord avec les infectiologues, un protocole d’antibiothérapie probabiliste adaptée. Cette démarche nous a permis de constater une incidence faible de méticillino-résistance des Staphylocoques, une incidence nulle de Staphylocoque après un délai de pose du cathéter de plus de 6 mois, aucun Pseudomonas multirésistant et un très faible pourcentage d’entérobactérie résistant aux céphalosporines. La mise à jour régulière de l’épidémiologie microbiologique des bactériémies liées aux cathéters d’hémodialyse, associée à un partenariat avec l’équipe d’infectiologie dans son centre d’hémodialyse, permettant une adaptation de l’antibiothérapie probabiliste, paraît avoir une bonne faisabilité et, à long terme, favoriser la préservation de l’écologie microbienne à l’échelle individuelle et collective pour la population de patients traités par hémodialyse. Patients in hemodialysis on central venous catheter as vascular access are at risk of infections. Catheter-related bloodstream infection is one of the most serious catheter-complications in hemodialysis patients. Its clinical and microbiological diagnosis is challenging. The implementation of empiric antibiotic therapy is based on old recommendations proposing the combination of a molecule targeting methicillin-resistant Staphylococcus aureus and a betalactamin active on P. aeruginosa, and also adapting this probabilistic treatment by carrying out a microbiological register on a local scale, which is rarely done. In our hemodialysis center at Bordeaux University Hospital, an analysis of the microorganisms causing all catheter-related bloodstream infection over the period 2018–2020 enabled us to propose, in agreement with the infectious disease specialists, an adapted probabilistic antibiotic therapy protocol. This approach allowed us to observe a low incidence of meticillinoresistance of Staphylococcus. For catheters inserted more than 6 months ago, we observed no Staphylococcus, no multi-resistant Pseudomonas, and only 2% of Enterobacteria resistant to cephalosporins. A frequent updating of the microbiological epidemiology of catheter-related bloodstream infection, in partnership with the infectious diseases team in each hemodialysis center, allowing an adaptation of the probabilistic antibiotic therapy, and seems to have a good feasibility. This strategy might favor the preservation of microbial ecology on an individual and collective scale in maintenance hemodialysis patients.